Search for: "Eli Lilly "
Results 1541 - 1560
of 2,131
Sort by Relevance
|
Sort by Date
10 Jan 2010, 3:30 pm
Justice Floyd's refusal to revoke Eli Lily's European patent for olanzapine (see Dr Reddy's Laboratories (UK) Ltd v Eli Lilly & Company Ltd. [2008] EWHC 2345 (Pat), [2009] [read post]
8 Jan 2010, 5:17 am
"Eli Lilly and Company v. [read post]
7 Jan 2010, 5:52 am
Tom Lamb and the Drug Injury Watch have a good article on the selective information given by Amylin Pharmaceuticals about their diabetes drug Byetta (co-marketed with Eli Lilly) to the media and their investors in October, 2009. [read post]
6 Jan 2010, 2:05 pm
From a December 23, 2009 Bloomberg article, "Amylin Falls as Analyst Says FDA Wants Byetta Study", by reporter Rob Waters: San Diego-based Amylin and Indianapolis-based Eli Lilly & Co., which co-market the drug, announced Oct. 30 that the Food and Drug Administration had cleared the drug for use as standalone therapy for Type 2 diabetics and that prescribing information would warn about the risk of pancreatitis, an inflamed pancreas, in patients with severe… [read post]
6 Jan 2010, 3:32 am
(Patent Docs) Products Angiomax (Bivalirudin) – US: Medicines Company files patent infringement complaints against Pliva Hrvatska and Teva following Para IV challenge (Patent Docs) (Patent Docs) (IP Factor) Emend (Fosaprepitant dimeglumine) – US: FDA issues exclusivity decision for Merck’s Emend; Agency reverses course and grants NCE exclusivity (FDA Law Blog) Gemzar (Gemcitabine) – US: Eli Lilly in new patent fight for chemotherapy drug (GenericsWeb)… [read post]
5 Jan 2010, 6:58 pm
Also approved were a new blood thinner from Eli Lilly & Co. [read post]
29 Dec 2009, 9:09 pm
Miller, Vice President of Corporate Business Development, Eli Lilly Reid Leonard, Vice President External Licensing and Business Development, Merck Jules Musling, VP, Johnson & Johnson Carlos Garrido, Finance Director , Head of Strategic Planning and Business Development South America, AstraZeneca Peter Verheyen, VP Business Development, Johnson & Johnson Michael Lytton, EVP Business Development, Biogen Idec Inc Mark Dennish, Vice President, Business Development, Daiichi… [read post]
29 Dec 2009, 9:09 pm
Miller, Vice President of Corporate Business Development, Eli Lilly Reid Leonard, Vice President External Licensing and Business Development, Merck Jules Musling, VP, Johnson & Johnson Carlos Garrido, Finance Director , Head of Strategic Planning and Business Development South America, AstraZeneca Peter Verheyen, VP Business Development, Johnson & Johnson Michael Lytton, EVP Business Development, Biogen Idec Inc Mark Dennish, Vice President, Business Development, Daiichi… [read post]
24 Dec 2009, 12:28 am
In dismissing the breach of express warranty claim, the judge said the fund didn't directly receive any express warranties from Eli Lilly. [read post]
23 Dec 2009, 12:40 am
Sandoz Limited (EPLAW) Fuzeon (Enfuvirtide) - US: If there are no sources of proof in the E D of Texas, expect to transferred: In re Hoffman-La Roche Inc (Filewrapper) Gemzar (Gemcitabine) – US: Eli Lilly appeals from grant of partial summary judgment finding certain claims invalid for double patenting: Sun Pharma v Eli Lilly (PATracer) Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against APP… [read post]
22 Dec 2009, 2:42 pm
According to Dr Reddy's, the patent was a pretty sick one since it suffered from (i) an acute deficiency of novelty over a prior disclosure made by Eli Lilly in an earlier patent; (ii) glaring obviousnessness over the same patent and (iii) a further bout of obviousness which had been brought about by the earlier publication of an article by one of Eli Lilly's scientists. [read post]
22 Dec 2009, 10:08 am
Recently there have been a number of settlements and even guilty pleas by pharmaceutical manufacturers, including AstraZeneca ($550 million), Pfizer ($2.3 billion) and Eli Lilly ($1.4 billion) related to other unlawful marketing practices. [read post]
21 Dec 2009, 12:24 am
The Court dismissed Dr Reddy's appeal against the decision of Mr Justice Floyd (noted by the IPKat here) not to revoke Eli Lilly's patent for the anti-psychotic olanzapine. [read post]
20 Dec 2009, 8:16 pm
Eli Lilly and Company v. [read post]
16 Dec 2009, 3:39 am
Eli Lilly & Co. [read post]
14 Dec 2009, 9:59 pm
Eli Lilly & Co. last week, Chief Judge Michel asked Lilly's counsel whether Lilly had preserved the written description issue by timely objecting to District Court Judge Zobel's jury instruction (see "Ariad v. [read post]
14 Dec 2009, 4:38 pm
Eli Lilly & Co. (1988) 44 Cal.3d. 1103, it starts running when the plaintiff suspects or should suspect that he or she has been wronged. . . . [read post]
14 Dec 2009, 2:02 pm
Eli Lilly. [read post]
14 Dec 2009, 2:02 pm
Eli Lilly. [read post]
11 Dec 2009, 11:47 am
Eli Lilly & Co., 2009 WL 4768195, slip op. [read post]
